Navigation Links
ArmaGen® Re-engineers Erythropoietin for Brain Penetration
Date:7/16/2010

LOS ANGELES, July 16 /PRNewswire/ -- Human erythropoietin (EPO) is a potent neuroprotective agent for multiple brain disorders, including stroke, brain and spinal cord injury, and Parkinson's disease. However, EPO drug development for the brain is limited, because EPO does not cross the blood-brain barrier (BBB). In acute stroke or brain injury, the BBB is intact in the early hours after the insult when neuroprotection is still possible. Therefore, large molecule biopharmaceuticals such as EPO must be re-engineered to enable BBB transport. ArmaGen Technologies has developed the BBB molecular Trojan horse platform technology for solving the BBB drug delivery problem, and has used this technology to create a brain penetrating form of human EPO. ArmaGen® has successfully re-engineered human EPO as an IgG fusion protein that penetrates the brain following intravenous (IV) administration. Human EPO is fused to a genetically engineered monoclonal antibody (MAb) to the human insulin receptor (HIR). The HIRMAb acts as a molecular Trojan horse to ferry the EPO across the BBB via transport on the endogenous BBB insulin receptor. The HIRMAb-EPO fusion protein is a dual receptor specific protein with low nM binding constants for both the human EPO receptor and the human insulin receptor. The HIRMAb part of the HIRMAb-EPO fusion protein cross-reacts with the Rhesus monkey insulin receptor. Therefore, brain penetration of the HIRMAb-EPO fusion protein was demonstrated in vivo in the adult Rhesus monkey following IV administration.  EPO alone was shown not to cross the primate BBB. The brain uptake of the HIRMAb-EPO fusion protein in the Rhesus monkey is high, 2% injected dose/brain, and comparable to the brain uptake of small molecules. The plasma pharmacokinetics (PK) of the HIRMAb-EPO fusion protein differs markedly from the PK of EPO, which minimizes any effect of the fusion protein on erythropoiesis. EPO-driven neuroprotection in human brain disorders is now possible with systemic administration of the HIRMAb-EPO fusion protein at doses that have minimal effects on erythropoiesis. The work is published in the June, 2010 issue of the Journal of Pharmacology and Experimental Therapeutics.

About ArmaGen® Technologies

ArmaGen® Technologies is a privately-held biotechnology company developing therapeutic products for the central nervous system. ArmaGen® re-engineers recombinant proteins to enable transport across the BBB. With ArmaGen®'s proprietary molecular Trojan horse technology, any recombinant protein can be re-engineered as a new brain penetrating neuropharmaceutical. For more information on ArmaGen® Technologies, visit the Company's Web site at www.armagen.com.


'/>"/>
SOURCE ArmaGen Technologies
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Anemic Patients With MDS Gain Long-Term Benefits From Erythropoietin and Myeloid Growth Factor Hormones
2. XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma
3. Statement by KCP Chairman Dr. Edward Jones in Response to FDA Advisory Committee on Benefits and Risks of Erythropoietin-Stimulating Agents in Treatment of Kidney Patients
4. Unprecedented Donation Made by Mrs. Lily Safra to the Institute for Brain and Spinal Cord Disorders in Paris
5. Physicians See New Benefits, Treatment Opportunities for Brain Cancer with Elektas Leksell Gamma Knife Perfexion
6. Brainlab Collaborates With Toshiba Medical Systems on Integrated Surgical Suite
7. Kendle Advances Early Stage Drug Development with ElMindAs Innovative Brain Network Activation Technology
8. Gamma Knife Users Share Latest Advances for Treating Cancer, Other Brain Disorders at Society Meeting in Greece
9. Elekta Opens a New Window into Human Brain Activity, Focuses on Brain Mets at 2010 AANS Meeting
10. Karolinska University Hospital Acquires Leksell Gamma Knife Perfexion to Expand Radiosurgery Versatility, Efficiency in Brain Cancer Therapy
11. Celtic Pharma Announces Initiation of Pediatric Dose Tolerance Trial Evaluating XERECEPT(R) in Pediatric Patients with Primary and Metastatic Brain Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 ... Markets has announced the addition of the " ... offering. This ... and provides an updated review, including its applications in ... the total market, which includes three main industries: pharmaceutical ...
(Date:6/24/2016)... June 24, 2016 Dehaier Medical Systems Ltd. ... which develops, markets and sells medical devices and wearable ... signed a strategic cooperation agreement with Hongyuan Supply Chain ... Chain") on June 20, 2016, to develop Dehaier,s new ... cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s sales ...
(Date:6/24/2016)... India , June 24, 2016 ... Needles Market by Type (Standard Pen Needles, Safety Pen ... Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, ... by MarketsandMarkets, This report studies the market for the ... expected to reach USD 2.81 Billion by 2021 from ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain ... for a minimum wage raise to $12 an hour by 2020 and then adjusting it ... the lost value of the minimum wage, assure the wage floor does not erode again, ...
Breaking Medicine News(10 mins):